ClinicalTrials.gg
CompletedNCT05027568Updated Mar 20, 2025

A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers

A Phase 1 interventional study of IOA-289 and Nab paclitaxel / gemcitabine in Healthy, sponsored by iOnctura. Completed at 1 site in Italy. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by iOnctura · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The purpose of Part 1 of this First-in-Human trial is to evaluate the safety and tolerability after single ascending oral doses of IOA-289 given to healthy male subjects, compared to placebo. After the oral dose administrations, the amount of IOA-289 present in serum will be determined for pharmacokinetic characterisation. Also the reduction of LPA in plasma will be determined as a pharmacodynamic biomarker.

Part 2 is optional and its conduct will be dependent on the pharmacokinetic data generated in Part 1. Part 2 will be a randomized, crossover, open label, single oral dose administration of IOA-289 to healthy male subjects either in a fasted state, or after a high-fat meal.

02

Conditions studied

  • Healthy

Keywords

  • Healthy subjects, effect of food, Roginolisib
03

In context

Lead sponsor

iOnctura is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects between 18 and 50 years of age (inclusive) at the screening visit
  • between 18.0 and 30.0 kg/m2 (inclusive) at the screening visit
  • In good health as determined by medical history, physical examination, , serum/urine, clinical chemistry, haematology, and serology tests
  • Able to provide written, prior to initiation of any trial-related procedures, and able, in the opinion of the Principal Investigator, to comply with all the requirements of the trial
  • Male subjects who are surgically sterile (i.e., have undergone bilateral orchidectomy); and male subjects who agree to remain abstinent or to practice double-barrier forms of and refrain from sperm donation from trial screening through 90 days from the last dose of IMP

Exclusion criteria

Exclusion Criteria:

  • abnormality in past medical history, or at the screening physical examination, that in the Investigator's or Sponsor's opinion may place the subject at risk or interfere with outcome variables including absorption, distribution, metabolism, and excretion of IMP
  • History of drug and/or alcohol abuse within 2 years prior to the screening visit
  • History of or current hepatitis or acquired immunodeficiency syndrome or carriers of , anti-, and/or antibodies
  • History of any significant drug allergy
  • Positive alcohol breath test and/or urine drug screen for substance of abuse at the screening visit or upon check-in to the clinical trial site
  • History of having taken an drug within 30 days preceding trial entry
  • History of significant bleeding or haemorrhagic tendencies
  • Donation of blood or plasma within 30 days prior to dosing
  • Use of prescription medication, over-the-counter medication, herbal medication, or vitamin supplements within 14 days prior to dosing and antibiotics within 30 days prior to dosing. The Sponsor may allow exceptions only if the medication's administration is deemed unlikely to impact the PK result
  • Exposure to any substances known to stimulate hepatic microsomal enzymes within 30 days prior to screening (e.g., occupational exposure to pesticides, organic solvents)
  • Supine blood pressure, after resting for ≥3 minutes, higher than 140/90 mmHg or lower than 100/50 mmHg. The Sponsor may allow exceptions if they are not deemed clinically significant
  • Supine pulse rate, after resting for ≥3 minutes, outside the range of 50 to 90 bpm. The Sponsor may allow exceptions if they are not deemed clinically significant
  • History of serious mental disorders that, in the opinion of the Investigator, would exclude the subject from participating in this trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    IOA-289 daily oral dosing plus gemcitabine and nabpaclitaxel every 3 weeks starting on Day 8

    Drug: IOA-289 · Drug: Nab paclitaxel / gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Numbers of participants with treatment-related adverse events as assessed by MedDRA v24

    Adverse Events will be assessed by nondirective questioning of the participants during the screening process and at each visit during the study

    Time frame: Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose

Secondary outcomes

  1. Pharmacokinetic profile of IOA-289

    Blood samples for plasma IOA-289 concentrations

    Time frame: Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose

  2. Cmax

    The maximum observed plasma concentration

    Time frame: Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose

  3. Tmax

    The time at which Cmax occurs

    Time frame: Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose

  4. AUCinf

    The area under the plasma concentration-time curve from time of dosing to infinity

    Time frame: Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose

  5. To determine the change from baseline of LPA levels

    Measurement of LPA levels in plasma

    Time frame: Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose

07

Study locations

1 site
  • Centro Ricerche Cliniche di Verona srl
    Verona, 37134, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Sep 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2021
First posted
Aug 30, 2021
StartActual
Jun 28, 2021
Primary completionActual
Sep 7, 2021
CompletionActual
Sep 7, 2021
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05027568
Lead sponsor
iOnctura
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Jun 28, 2021
Primary completion
Sep 7, 2021
Completion
Sep 7, 2021
Last update
Mar 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion